Solid Third-Quarter Results
Revenue increased 15.1% year over year to $165.2 million, driven by strong performances in Asia Pacific, North America and Europe.
Based on the strong third-quarter results, USANA Health Sciences raised its outlook for 2012. Net sales are now expected to reach $645 million, up from the previous range of $630 million to $640 million.
The company also raised its 2012 earnings guidance to between $4.35 and $4.40 per share from the previous range of $4.10 to $4.20. USANA Health Sciences expects the strong performance to continue due to the Lifetime Matching Bonus and other initiatives.
Earnings Estimates on the Rise
The Zacks Consensus Estimate for 2012 rose 4.5% to $4.39 per share in the last 60 days, as all five estimates were revised upward. This represents a year-over-year increase of 34.6%.
The Zacks Consensus Estimate for 2013 grew 4.8% to $4.84 per share over the same time frame as all five estimates again were raised. This reflects a year-over-year increase of 10.4%.
The year-to-date return for the stock is 36.3%. Volume is quite strong, averaging roughly 228K daily.
USANA Health Sciences is focused on the development and manufacturing of nutritionals and personal care products. The company, which sells its products through a global network marketing system, operates primarily in two geographic regions: North America/Europe and Asia Pacific. Primary product lines at USANA Health consist of USANA Nutritionals (Essentials and Optimizers), USANA Foods, and Sensé. Founded in 1992, the company has a market cap of $620.1 million and competes with Mannatech Inc. (MTEX).Read the full Snapshot Report on USNA (email registration required)
Read the full on MTEX (email registration required)